Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 170.80 INR
Change Today 0.00 / 0.00%
Volume 0.0
DISH On Other Exchanges
Symbol
Exchange
Natl India
As of 7:05 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

dishman pharmaceuticals & ch (DISH) Snapshot

Open
173.95
Previous Close
174.30
Day High
174.70
Day Low
169.60
52 Week High
09/22/14 - 197.00
52 Week Low
05/19/14 - 81.00
Market Cap
13.8B
Average Volume 10 Days
890.1K
EPS TTM
13.54
Shares Outstanding
80.7M
EX-Date
08/21/14
P/E TM
12.6x
Dividend
1.20
Dividend Yield
0.70%
Current Stock Chart for DISHMAN PHARMACEUTICALS & CH (DISH)

Related News

No related news articles were found.

dishman pharmaceuticals & ch (DISH) Related Businessweek News

No Related Businessweek News Found

dishman pharmaceuticals & ch (DISH) Details

Dishman Pharmaceuticals and Chemicals Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide. It offers contract services, including process research and active pharmaceutical ingredients (APIs) supply to support early phase clinical trials; process development and optimization; cGMP manufacture; and commercial supply services. The company also manufactures and markets bulk drugs, intermediates, fine chemicals, quaternary ammonium compounds (Quats), and specialty chemicals. Its products include various vitamins and chemical products, such as Vitamin D, Vitamin D analogues, cholesterol, and lanolin related products; and specialty chemicals, including ammonium and phosphonium Quats, phosphoranes and wittig reagents, bulk API and intermediates, phase transfer catalysts, fine chemicals, and outsourced products for the pharmaceutical, cosmetic, and related industries. The company also offers a range of antiseptics and disinfectants, including disinfectants for surgical instrumentation, hand and body wash sanitizers and antiseptics, pre and post-operative surgical scrubs, and antimicrobial washes for healthcare and related industries. Dishman Pharmaceuticals and Chemicals Limited was incorporated in 1983 and is headquartered in Ahmedabad, India.

Founded in 1983

dishman pharmaceuticals & ch (DISH) Top Compensated Officers

Chairman, Managing Director, Chairman of Corp...
Total Annual Compensation: 61.0M
Managing Director, Whole-Time Director and Me...
Total Annual Compensation: 12.0M
Whole-Time Director
Total Annual Compensation: 12.0M
Compensation as of Fiscal Year 2014.

dishman pharmaceuticals & ch (DISH) Key Developments

Dishman Pharmaceuticals and Chemicals Appoints Rajendra S. Shah as an Additional Independent Director

Dishman Pharmaceuticals and Chemicals Ltd. has announced that the board of directors vide circular resolution dated April 02, 2015, have approved the appointment of Mr. Rajendra S. Shah as an Additional Director of the company. Mr. Rajendra S. Shah shall hold office as an Additional Director, effective from April 02, 2015 till the upcoming annual general meeting of the company. The board has considered him as an Independent Director in terms of the provisions of the Companies Act, 2013 and Listing Agreement.

Dishman Pharmaceuticals and Chemicals Ltd. Reports Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Dishman Pharmaceuticals and Chemicals Ltd. reported unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, on standalone basis, the company reported net sales /income from operations of INR 1,183.59 million compared to INR 1,042.37 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 304.91 million compared to INR 281.79 million a year ago. Profit from ordinary activities before tax was INR 143.72 million against INR 160.17 million a year ago. Net profit was INR 80.45 million or INR 1.00 per basic and diluted share before and after extraordinary items compared to INR 105.51 million or INR 1.31 per basic and diluted share before and after extraordinary items a year ago. For the nine months, on standalone basis, the company reported net sales /income from operations of INR 3,173.93 million compared to INR 3,151.88 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 712.98 million compared to INR 728.07 million a year ago. Profit from ordinary activities before tax was INR 526.27 million against INR 260.34 million a year ago. Net profit was INR 350 million or INR 4.34 per basic and diluted share before and after extraordinary items compared to INR 169.92 million or INR 2.11 per basic and diluted share before and after extraordinary items a year ago. For the quarter, on consolidated basis, the company reported net sales /income from operations of INR 3,858.43 million compared to INR 3,134.24 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 484.53 million compared to INR 351.11 million a year ago. Profit from ordinary activities before tax was INR 305.61 million against INR 198.75 million a year ago. Net profit was INR 240.34 million or INR 2.98 per basic and diluted share before and after extraordinary items compared to INR 151.56 million or INR 1.88 per basic and diluted share before and after extraordinary items a year ago. For the nine months, on consolidated basis, the company reported net sales /income from operations of INR 11,397.27 million compared to INR 9,725.86 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 1,580.84 million compared to INR 1,651.9 million a year ago. Profit from ordinary activities before tax was INR 1,066.41 million against INR 1,059.3 million a year ago. Net profit was INR 811.68 million or INR 10.06 per basic and diluted share before and after extraordinary items compared to INR 866.76 million or INR 10.74 per basic and diluted share before and after extraordinary items a year ago.

Dishman Pharmaceuticals and Chemicals Ltd., Q3 2015 Earnings Call, Feb 13, 2015

Dishman Pharmaceuticals and Chemicals Ltd., Q3 2015 Earnings Call, Feb 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DISH:IN 170.80 INR 0.00

DISH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Divi's Laboratories Ltd 1,894 INR 0.00
Jubilant Life Sciences Ltd 167.45 INR 0.00
Piramal Enterprises Ltd 943.45 INR 0.00
Shasun Pharmaceuticals Ltd 351.30 INR 0.00
Torrent Pharmaceuticals Ltd 1,281 INR 0.00
View Industry Companies
 

Industry Analysis

DISH

Industry Average

Valuation DISH Industry Range
Price/Earnings 13.5x
Price/Sales 0.9x
Price/Book 1.2x
Price/Cash Flow 6.6x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DISHMAN PHARMACEUTICALS & CH, please visit www.dishmangroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.